UPC_CoA_528/2024

ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)

BerufungenHauptberufungCourt of AppealAppealCase Closed

Dieser Fall zitiert

In den Entscheidungen dieses Falls zitierte Quellen.

Quelle	Rechtsfrage	Bindungskraft	Auszug
220.4	sufficiency — rehearing petition procedure	Bindend	Sanofi and Regeneron sought suspensive effect as part of a petition for rehearing (R. 220.4 RoP).
223	sufficiency — suspensive effect requires motivated request	Bindend	For appeals, there is an explicit requirement that a request for suspensive effect is motivated (Art. 74(1) UPCA and Rule 223 RoP).
265.1	withdrawal — conditions for permitting withdrawal of rehearing application	Bindend	Pursuant to R.265.1 RoP, as long as there is no final decision in an action, a claimant may, pursuant to R. 265.1 RoP, apply to withdraw his action.
245	withdrawal — rehearing procedure	Bindend	concerning an application for withdrawal (R. 265 RoP) regarding an application for rehearing (R. 245 RoP)
370.9	withdrawal — reimbursement of court fees	Bindend	and an application for reimbursement of Court fees (R. 370.9 RoP)

Quelle	Rechtsfrage	Bindungskraft	Auszug
74(1)	sufficiency — appeals do not have suspensive effect unless court decides otherwise	Bindend	a parallel may be drawn with appeals, which also do not have suspensive effect unless the Court decides otherwise (Art. 74(1) UPCA). For appeals, there is an explicit requirement that a request for suspensive effect is motivated (Art. 74(1) UPCA and Rule 223 RoP).
76	sufficiency — rehearing requirements	Bindend	In case the Court of Appeal were to consider that the decision dated 25 November 2025 satisfies the requirements of Art. 76 UPCA, Sanofi and Regeneron request the referral of a question to the European Court of Justice.

Zitiert in

Spätere UPC-Entscheidungen, die diesen Fall zitieren.

Zitiert in	Datum	Rechtsfrage	Bindungskraft	Auszug
UPC_CFI_337/2025 Munich CD	1. Dez. 2025	inventive step and sufficiency	Bindend	as well as cases UPC_CoA_528 and 529/2024 (Amgen/Sanofi and Regeneron). The submissions should address the legal implications of the aforementioned Court of Appeal decisions only
UPC_CoA_529/2024 Court of Appeal	25. Nov. 2025	sufficiency — test and inventive step analysis in PCSK9 antibody patent revocation	Bindend	UPC Court of Appeal UPC_CoA_528/2024 UPC_CoA_529/2024